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Abstract: A disproportionate burden of helminthiases in
human populations occurs in marginalised, low-income,
and resource-constrained regions of the world, with over
1 billion people in developing areas of sub-Saharan Africa,
Asia, and the Americas infected with one or more
helminth species. The morbidity caused by such infections
imposes a substantial burden of disease, contributing to a
vicious circle of infection, poverty, decreased productivity,
and inadequate socioeconomic development. Further-
more, helminth infection accentuates the morbidity of
malaria and HIV/AIDS, and impairs vaccine efficacy.
Polyparasitism is the norm in these populations, and
infections tend to be persistent. Hence, there is a great
need to reduce morbidity caused by helminth infections.
However, major deficiencies exist in diagnostics and
interventions, including vector control, drugs, and vac-
cines. Overcoming these deficiencies is hampered by
major gaps in knowledge of helminth biology and
transmission dynamics, platforms from which to help
develop such tools. The Disease Reference Group on
Helminths Infections (DRG4), established in 2009 by the
Special Programme for Research and Training in Tropical
Diseases (TDR), was given the mandate to review
helminthiases research and identify research priorities
and gaps. In this review, we provide an overview of the
forces driving the persistence of helminthiases as a public
health problem despite the many control initiatives that
have been put in place; identify the main obstacles that
impede progress towards their control and elimination;
and discuss recent advances, opportunities, and challeng-
es for the understanding of the biology, epidemiology,
and control of these infections. The helminth infections
that will be discussed include: onchocerciasis, lymphatic
filariasis, soil-transmitted helminthiases, schistosomiasis,
food-borne trematodiases, and taeniasis/cysticercosis.
Introduction
Since the publication by Norman Stoll in 1947 of ‘‘This Wormy
World’’ [1], where the intolerable burden of intestinal nematode
infections was highlighted, several global efforts have been made to
address the health effects of human parasitism by helminths.
Helminths (roundworm and flatworm parasites) are among the
most widespread infectious agents of human populations. Today,
they disproportionately affect marginalised, low-income, and
resource-constrained regions of the world. It is estimated that
over 1 billion people in developing regions areas of sub-Saharan
Africa (SSA), Asia, and the Americas are infected with one or more
species of helminths [2,3]. The morbidity associated with most of
the helminthic diseases we focus on in this report and in the other
reviews in this issue are closely linked to poverty; they result from
poverty and markedly contribute to further poverty by, among
others, impairing agricultural and economic productivity, and they
exert a detrimental impact on cognitive development and
educational outcomes, thereby hampering socioeconomic devel-
opment. Moreover, the infections themselves may accentuate the
effect of other significant pathogens such as malaria and HIV, and
attenuate the response to a range of vaccines.
In response to growing evidence demonstrating the devastating
impact of these neglected tropical diseases (NTDs) on the bottom
billion of the world population through their effects on health,
education, and socioeconomic development, the World Health
Assembly (WHA) has adopted several resolutions calling for the
control or elimination of these diseases, and for the implementation
of a number of large-scale control and elimination programmes.
Thesehavebeenaimedattheparasitesthemselvesand/ortheagents
(vectors and intermediate hosts) responsible for their transmission. In
1974, WHA resolution WHA27.52 was passed, calling upon the
World Health Organization (WHO) to intensify research on major
parasitic diseases. This led in 1975 to the creation of the Special
Programme for Training and Research in Tropical Diseases (TDR).
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www.plosntds.org 1 April 2012 | Volume 6 | Issue 4 | e1582That yearalsosawthe commencementofantivectorial operationsby
the Onchocerciasis Control Programme (OCP) in West Africa. In
1993 and 1995, respectively, the Onchocerciasis Elimination
Program for the Americas (OEPA) and the African Programme
for Onchocerciasis Control (APOC) were initiated. In 1997,
resolution WHA50.29 was passed, which urged the WHO and
member states to eliminate lymphatic filariasis (LF). This led to the
formation of the Global Programme to Eliminate Lymphatic
Filariasis (GPELF), which is supported by the Global Alliance to
Eliminate Lymphatic Filariasis (GAELF), a public–private partner-
shipthat waslaunched in2000 to support theGPELF infundraising,
advocacy, communications, resource mobilisation, and programme
implementation. In 2001, resolution WHA54.19 was passed, setting
the global target of treating by the year 2010 at least 75% of all
school-age children at risk of morbidity from soil-transmitted
helminthiases (STHs) and schistosomiasis. This resolution led to
the establishment of Partners for Parasite Control (PPC) by the
WHO. More recently, the global public health community has been
invigorated by the articulation of the Millennium Development
Goals (MDGs), which are: MDG1: Eradicate extreme poverty and
hunger; MDG2: Achieve universal primary education; MDG3:
Promote gender equality and empower women; MDG4: Reduce
child mortality; MDG5: Improve maternal health; MDG6: Combat
HIV/AIDS, malaria and other diseases; MDG7: Ensure environ-
mental sustainability; and MDG8: Develop a global partnership for
development [2,4]. Several new initiatives have been also been
established,mostnotably theSchistosomiasis Control Initiative(SCI)
in 2002 and the Global Network for Neglected Tropical Disease
Control (GNNTDC) in 2006.
However, despite such WHA/WHO resolutions, the initiatives
described above, and the many scientific advances in our
understanding of the biology and epidemiology of helminth
infections, obstacles remain that challenge the global public health
community in their efforts to attain the aims of controlling
morbidityand eliminatinginfection.Someoftheidentified obstacles
include the current scarcity of tools for: 1) updated disease mapping
(particularly as interventions progress); 2) new anthelmintics and
vaccines that would provide higher levels of control and greater
sustainability than currently available to the present control
measures; 3) improved, more sensitive diagnostics that are required
for specific activities, such as in elimination settings; 4) monitoring
the progress of control interventions and quantifying changes in
incidence of infection and disease; 5) assessing the efficacy of drug
and interventions to control vectors/intermediate hosts (e.g.,
insecticides) and promptly detecting possible development of
resistance to these; 6) determining programme end points (for
elimination of the public health burden and/or the infection
reservoir) and deciding when interventions could be safely stopped;
and 7) implementing post-control surveillance. Research gaps in
these and other areas, as well as inclusion of a research and
development agenda for human helminthiases for each of the topics
covered (interventions, diagnostics, basic biology, mathematical
modelling, social and environmental determinants, and capacity
building) have been the subject of deliberation by the Disease
Reference Group on Helminth Infections (DRG4), established in
2009 byTDR,andwill be further discussedindetailinthefollowing
reviews within this PLoS Neglected Tropical Diseases collection. Box 1
lists the abbreviations used in this paper.
Human Helminthiases, Populations at Risk, and
Resulting Diseases
Helminth parasites are parasitic worms from the phyla
Nematoda (roundworms) and Platyhelminthes (flatworms). To-
gether, they comprise the most common infectious agents of
humans in developing countries. The most common helminthiases
of humans are those caused by intestinal infection with STHs,
namely Ascarias lumbricoides, Trichuris trichiura, and hookworms
(Necator americanus and Ancylostoma duodenale), followed by schistoso-
miasis and lymphatic filariasis (LF). In Table 1 the estimated
number of people infected (although estimates are given
separately, there is a significant amount of co-infection), the
burden of disease (in terms of disability-adjusted life years
[DALYs]), and the estimated number of annual deaths attributable
to each disease, are summarised for each condition. The collective
burden of the common helminth diseases rivals that of the main
high-mortality conditions such as HIV/AIDS or malaria; 85% of
the NTD burden for the poorest 500 million people living in SSA
results from helminth infections. Of the 580 million people in
Latin America and the Caribbean, 241 million live in areas where
at least one of the NTDs is endemic [5,6]. Since the remit of the
series of these review papers is centered on the issues of identifying
research priorities for the improvement of helminth control
programmes, the infections described below are ordered not in
terms of their abundance but in terms of their history of
intervention, with the OCP in West Africa (1975–2002) being
the first large-scale programme to have been implemented
(originally based on vector control).
Onchocerciasis
Onchocerciasis (caused by infection with Onchocerca volvulus)
affects, according to recent estimates [7], 37 million people in 34
countries and is the second cause of infectious blindness after
trachoma, with 99% of the cases in SSA. In Latin America,
Box 1. List of Abbreviations
ADLA, acute dermatolymphangioadenitis
DALY, disability-adjusted life year
DRG4, Disease Reference Group on Helminth Infections
EST, expressed sequence tag
GIS, geographical information systems
GAELF, Global Alliance to Eliminate Lymphatic Filariasis
GNNTDC, Global Network for Neglected Tropical Disease
Control
GPELF, Global Programme to Eliminate Lymphatic Filari-
asis
LF, lymphatic filariasis
MDGs, Millennium Development Goals
MSAT, mass screen and treat
NCC, neurocysticercosis
NTDs, neglected tropical diseases
OCP, Onchocerciasis Control Programme in West Africa
M&E, monitoring and evaluation
OEPA, Onchocerciasis Elimination Program for the Amer-
icas
OSD, onchocercal skin disease
PPC, Partners for Parasite Control
REA, rapid epidemiological assessment
RNAi, RNA interference
RS, remote sensing
SCI, Schistosomiasis Control Initiative
STHs, soil-transmitted helminthiases
SSA, sub-Saharan Africa
TDR, Special Programme for Research and Training in
Tropical Diseases
WHA, World Health Assembly
WHO, World Health Organization
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Guatemala, Colombia, Ecuador, Venezuela, and Brazil), with 13
focal areas originally described, and 510,000 individuals estimated
to have been at risk of infection [7]. However, in eight of these
focal areas, there is encouraging evidence of interruption of
transmission after the implementation of the regional strategy
adopted by the OEPA [5,6]. Notably, most of these foci are small
and circumscribed, with probably not much genetic diversity in
the parasite population at any single focus, some (though not all) of
the blackfly vectors are less efficient than their African counter-
parts, and treatment with ivermectin has been more frequent
(biannually instead of yearly, and in some localities up to four
times per year) and has achieved a high coverage [8].
In onchocerciasis, morbidity is manifested as ocular involvement
including blindness, dermal involvement including skin disease and
palpable nodules, neuro-hormonal involvement including associa-
tions with epilepsy and hypo-sexual dwarfism (Nakalanga syndrome),
and lymphatic involvement including lymphadenopathy, hanging
groin, and lymphoedema. Although onchocercal ocular disease and
blindness are more prominent in African savannah regions,
onchodermatitis or onchocercal skin disease (OSD) has a higher
prevalence in forest areas, possibly because of differences in parasite
strains. The importance of OSD as a contributor to the disease
burden of onchocerciasis has been recognised relatively recently [9].
In 1995, the year APOC was implemented (and 25 years after the
commencement of the OCP), the burden of disease was estimated to
amount to 1.99 million DALYs lost because of onchocerciasis. In
2003, on the basis of updated mapping and treatment coverage data,
and assumed decreases in attributable morbidity due to skin and eye
disease, the DALYs due to onchocerciasis were re-estimated to have
reduced to 1.49 million [10].
Lymphatic Filariasis
LF is endemic in 83 countries and territories. It is estimated that
1.3 billion people are at risk for developing the disease, with some
120 million people being infected [11]. Over 40 million people are
seriously incapacitated and disfigured by the disease. Of these,
95% are infected with Wuchereria bancrofti, and the remainder with
Brugia malayi or Brugia timori [12]. The infection, usually acquired in
early childhood, causes considerable morbidity and social stigma
because of the deformities it produces. LF provokes acute
dermatolymphangioadenitis (ADLA) and lymphoedema. Major
chronic manifestations include hydrocoele and lymphoedema of
limbs, as well as chyluria, lymphoedema of the scrotum,
adenopathy, haematuria, and tropical pulmonary eosinophilia.
The disease causes permanent and long-term disability, and
damages and deforms the limbs, breasts, and genitals, resulting in
serious psychosocial consequences. Worldwide, 5 million DALYs
are lost annually due to LF [10]. The Southeast Asia region
accounts for about 57% of the total global burden. India’s
economic losses due to LF have been estimated at ,US$ 1 billion
per year [13].
Soil-Transmitted Helminthiases
The STHs are intestinal nematode infections and are among
the most common and persistent parasitic infections worldwide.
Table 1. The Worldwide Abundance, Burden of Disease, Distribution, and Control/Elimination Programmes of Human
Helminthiases.
Infection Causal Agent
Region with
Highest No.
Infected
Number Infected
(Millions) DALYs (Millions)
Number of Deaths/
Year (Thousands)
Programmes
Involved
Onchocerciasis Onchocerca volvulus SSA 37 1.5
a 0.05 (in the OCP area)
b OCP, APOC, OEPA
Lymphatic filariasis Wuchereria bancrofti;
Brugia malayi
India, SEA, SSA 120 5.8 0.4 GPELF
Ascariasis Ascaris lumbricoides Asia, Africa, LA 1,221–1,472
c 1.8–10.5
c 3–60
c PPC, DtW, GPELF, SCI
Trichuriasis Trichuris trichiura Asia, Africa, LA 759–1,050
c 1.0–6.4
c 3–10
c PPC, DtW, GPELF, SCI
Hookworm infection Necator americanus;
Ancylostoma duodenale
Asia, Africa, LA 740–1,300
c 0.1–22.1
c 3–65
c PPC, DtW, GPELF, SCI
Schistosomiasis S. mansoni
S. haematobium
S. japonicum
SSA, LA
SSA
China, SEA
207 1.7–4.5
c 15–280
c SCI in SSA; national
programmes elsewhere
Food-borne trematodiases Clonorchis sinensis;
Opisthorchis viverinni;
Paragonimus spp.;
Fasciolopsis buski;
Fasciola hepatica
East Asia 56
d 0.5–0.9
d 7
d Large-scale control
initiatives lacking
Cestode infections:
cysticercosis
Taenia solium SSA, Asia, LA 0.4 (LA only) ND ND Large-scale control
initiatives are lacking
Modified from references [2,3,10,14–16,36,77,120].
aFrom Remme et al. [10].
bFrom Little et al. [120].
cFrom Utzinger and Keiser [14].
dFrom Fu ¨rst et al. [36].
Abbreviations: SSA, sub-Saharan Africa; SEA, Southeast Asia; LA, Latin America; OCP, Onchocerciasis Control Programme in West Africa (1975–2002); APOC, African
Programme for Onchocerciasis Control (1995–ongoing); OEPA, Onchocerciasis Elimination Program for the Americas (1993–ongoing); GPELF, Global Program to
Eliminate Lymphatic Filariasis (2002–ongoing); PPC, Partners for Parasite Control (2001–ongoing); DtW, Deworm the World (2007–ongoing); SCI, Schistosomiasis Control
Initiative (2002–ongoing).
doi:10.1371/journal.pntd.0001582.t001
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infected with roundworm (A. lumbricoides), 795–1050 million with
whipworm (T. trichiura), and 740–1300 million with hookworm (N.
americanus, A. duodenale) [14]. Although not mentioned further in
this report, it is worth noting that an unknown, but estimated 30–
100 million people are infected with threadworm (Strongyloides
stercoralis) [15]. The morbidity attributable to this lifelong infection
is poorly studied but the serious morbidity and mortality it causes
in immuno-suppressed individuals continues to be reported in the
medical literature [3,16]. In Latin America and the Caribbean,
STHs are present in all countries with an estimated 26.3 million
school-age children at risk of infection. In 13 of the 14 countries in
this region, many areas have an infection prevalence higher than
20% [5,6,17]. Globally, approximately 300 million people suffer
from severe morbidity that results in 10,000–135,000 deaths
annually. However, their greatest impact is through the impair-
ment of physical and mental development in children, which
ultimately retards educational advancement and economic
productivity. The relationship between hookworm infection and
anaemia is well recognised, with numerous intervention trials
showing a direct effect of cure of infection with reduction in
prevalence and intensity of iron deficiency anaemia. However, for
A. lumbricoides and T. trichiura infection, the relationship between
infection and specific morbidity measures is less well established.
The uncommon, but potentially severe, adverse clinical outcomes
of rectal prolapse due to T. trichiura infection and bile duct or
intestinal obstruction due to A. lumbricoides infection are well
recognised in the medical literature. However, there is a lack of
epidemiological data defining the prevalence of these complica-
tions, and relating them to community prevalence and infection
intensity [18–20]. Less easily measured parameters such as
hypoproteinemia have been attributed to heavy infection with
these parasites, but likewise there is a dearth of quality
epidemiological data. Studies have been undertaken to relate
school, cognitive, and athletic performance to infection, largely
through chemotherapy interventions. While there appears to be
some effect, distinguishing this from other coexisting confounding
variables such as micro- and macronutrient deficiency is not
straightforward.
Schistosomiasis
Schistosomiasis is endemic in 76 countries and territories in the
tropics and subtropics. Schistosoma mansoni is endemic in 54
countries and S. haematobium in 55 [21]. Infection by S. japonicum
remains an important public health burden in the Philippines,
China, and parts of Indonesia, despite continued efforts by
ongoing control programmes [22]. Worldwide, almost 800 million
individuals are at risk; about 200 million people are estimated to
be infected, and over half of these have various degrees of
morbidity [23–25]. Of the 200 million people infected with
Schistosoma spp. in the world, 160 live in SSA, where approximately
110 million are infected with S. haematobium [26]. Schistosomiasis
causes 15,000–280,000 deaths annually in SSA alone [26] and
severe disability in approximately 20 million people. In its chronic
stage, the disease is associated with liver and bladder cancer.
Infection with S. haematobium is particularly burdensome, causing
a large number of cases of hydronephrosis, renal failure, and
bladder cancer. Women with urinary/genital schistosomiasis are
at an increased risk of acquiring HIV infection [27]. Over 80% of
the schistosomiasis burden is concentrated in SSA. In Latin
America and the Caribbean, S. mansoni infection is prevalent in
four countries: Brazil, Saint Lucia, Suriname, and Venezuela, with
25 million people at risk of infection and 1–3 million people
infected. The figures presented in Table 1 (corresponding to the
Global Burden of Disease estimates for 2000 and updated in 2004)
are thought to considerably underestimate the true burden of
schistosomiasis [28,29]. As for almost all helminth infections,
schistosome infection is not equivalent to schistosomiasis disease.
Likewise, there is a paucity of validated direct and indirect
indicators of schistosome-related morbidity [30–33]. In urinary
schistosomiasis, macroscopic haematuria is an obvious early sign of
morbidity. However, for S. mansoni and S. japonicum, assessment of
morbidity is more difficult. Furthermore, few, if any, of the clinical
manifestations of schistosomiasis are specific and overlap with
other causes, including other helminth infections, malaria, and
viral hepatitis, which often are co-endemic with schistosomiasis.
Food-Borne Trematodiases
Food-borne trematodiases, including liver flukes (Opisthorchis
viverrini, Op. felineus, and Clonorchis sinensis) and lung flukes
(Paragonimus spp.), remain important public health problems,
particularly in Asia. Chronic infections with Op. viverrini and C.
sinensis have long been associated with cholangiocarcinoma (bile
duct cancer). C. sinensis is widespread in China, Korea, and
Vietnam, while Op. viverrini is endemic in Southeast Asia, including
Thailand, Lao People’s Democratic Republic (Lao PDR),
Cambodia, and central Vietnam. Recent reports suggest that
about 35 million people globally are infected with C. sinensis, with
up to 15 million human infections in China alone and another 10
million individuals infected with Op. viverrini in Thailand and Lao
PDR. In a recent review it was estimated that 80 million people in
Thailand, Lao PDR, Cambodia, Vietnam, and Eastern Europe
are at risk for infection with Op. viverrini and Op. felineus. Over 45
million people are infected by both liver flukes Op. viverrini and C.
sinensis. More than 600 million people, mainly in Asia, including
China, Korea, Taiwan, and Vietnam, are at risk of infection [34].
The infections are associated with hepatobiliary diseases including
hepatomegaly, cholangitis, fibrosis of the periportal system,
cholecystitis, gallstone disease, and, importantly, are major
precipitants of cholangiocarcinoma. The liver fluke–endemic area
of Khon Kaen in northeast Thailand has reported the highest
incidence of this liver cancer in the world [35]. Indeed, liver and
bile duct cancers, end-stage consequences of liver fluke disease,
rank number five in Thai males and number six in females among
all diseases in terms of DALYs in 2005. About 56.2 million people
were infected with food-borne trematodes in 2005, 7.9 million had
severe sequelae, and 7,158 died, mostly from cholangiocarcinoma
and cerebral infection. Taken together, the global burden of food-
borne trematodiasis was estimated at 665,352 DALYs (ranging
from 479,496 to 859,051) [36].
Taeniasis/Cysticercosis
Human infections with the cestode parasite Taenia solium are
endemic in Latin America, most parts of Asia (including China
and the Indian subcontinent), Eastern Europe, and most of Africa.
Imported cases occur in most developed countries due to
immigration from and tourism to endemic regions. T. solium
infection, which causes intestinal taeniasis and tissue cysticercosis,
represent two different life stages and clinical entities in the human
host. Intestinal taeniasis with the adult tapeworm (when humans
act as definitive hosts) causes low morbidity by itself, but represents
the sole source of the more pathogenic tissue infection, designated
cysticercosis, that affects both humans and pigs. Cysticercosis, the
infection with the larval stage of the parasite or cysticercus (when
humans act as ‘‘intermediate hosts’’), is a major cause of seizure
disorders worldwide (human neurocysticercosis or NCC), and also
causes economic losses due to infected pork (porcine cysticercosis).
The most consistent indicator of the prevalence of neurocysticer-
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America, the attributed fraction for NCC is around 30% of all
seizure disorders, with this estimate also being consistent among
people with epilepsy worldwide [37]. Subarachnoid NCC is also
associated with intracranial hypertension and mortality.
Notably, the prevalence of NCC worldwide remains still
unknown. However, initiatives are currently underway to
determine the burden of NCC in endemic countries of Africa,
Asia, and Latin America [37–39] as well as in industrialised
countries such as the United States where it is becoming a better
recognised and possibly an increasing problem, the latter because
of immigration of tapeworm carriers from endemic areas. As the
estimate for the proportion of NCC among people with epilepsy is
very robust [37], it could be used, in conjunction with estimates of
the prevalence and incidence of epilepsy, to estimate this
component of the burden of NCC in endemic areas.
Distribution and Co-Occurrence
Epidemiologically, human helminthiases are characterised by
long-lasting infection with one or, more often, more than one of
the helminth species referred to above. This phenomenon, known
as polyparasitism, is the result of commonalities in ecological and
environmental requirements, infection routes, host exposures, and
susceptibility, as well as behavioural, sociological, and economic
factors that enable co-occurrence of a multiplicity of parasite–host
systems in time and space. In Figure 1, the geographical
distribution of co-occurrence of helminth species (LF, onchocer-
ciasis, schistosomiasis, and STHs) at country level is presented.
As studies have demonstrated that individuals infected with
multiple helminth species may also have the most intense
infections [40–44], polyparasitism may have a greater impact on
morbidity than the sum of single-species infections. In addition,
multiple species infections may increase susceptibility to other
infections, such as malaria or HIV [45,46], particularly given the
often detrimental immunomodulatory effect of helminth infec-
tions. Consequently, efforts have been made to better understand
the consequences of the co-existence of parasites within the same
host on the immunological responses to each species and, more
importantly, whether such interactions affect resistance, suscepti-
bility, or clinical outcome [47]. Co-infections are also shifting some
of the prevention and control measures of helminth infections
Figure 1. Geographical distribution of co-infections with helminth infections, 2009. The helminth infections include: lymphatic filariasis (LF),
onchocerciasis (Oncho), schistosomiasis (SCH), and soil-transmitted helminthiases (STH). The different colors represent the following co-infections:
STH+SCH+Oncho+LF; STH+SCH+LF; STH+SCH+Oncho; STH+Oncho; STH+SCH; STH+LF; and only STH. The information is based on reference [119].
doi:10.1371/journal.pntd.0001582.g001
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simultaneously target as many as four of the helminth NTDs,
including onchocerciasis, LF, STHs, and schistosomiasis—a
mission undertaken by the GNNTDC and the WHO [2,48].
Advances, Opportunities, and Challenges for the
Control and Elimination of Human Helminthiases
Improvement of environmental conditions, increased hygiene,
access to clean and potable water, better housing, and sustained
socioeconomic development have been demonstrated to be
essential for the elimination of helminth infections (the reason
many of these infections, previously prevalent in presently
industrialised countries, are no longer endemic in such areas).
Despite this, treatment of populations with anthelmintics in the
modality of mass drug administration (MDA), referred to as
preventive chemotherapy via community-based distribution sys-
tems and through schools, has become the predominant tool for
helminthiasis control in developing countries, either as targeted
treatment (to particular occupational or age groups), or among
whole communities, since they appear to be among the most cost-
effective global public health control measures [49–51]. Not only
does MDA obviate the costly requirement for mass screening and
diagnosis, but also drug donation programmes have been initiated
by highly visible pharmaceutical companies (such as the Mectizan
Donation Program of Merck & Co. for onchocerciasis and LF
control/elimination with ivermectin, in coordination with alben-
dazole donation by GlaxoSmithKline for LF and STHs [52]).
Additionally, patents have expired for some compounds, making
generic preparations (such as praziquantel for schistosomiasis, or
diethylcarbamazine for LF) highly affordable. The anthelmintic
drugs thus available to the control programmes are safe for mass
treatment of human populations and moderately to highly (albeit
variably) efficacious (see review by Prichard et al. in this issue for a
summary and discussion on anthelmintic efficacy [53]).
MDA is being assisted by global partnerships, including the
aforementioned donations from pharmaceutical companies of
anthelmintic drugs and financial support from foundations,
governments, United Nations agencies, companies, and individ-
uals. Efforts to integrate various MDA programmes may bring
logistic benefits to intervention programmes. However, it should
also be recognised that very little funding is available to support
operational research that is essential for such interventions to
remain sustainable and bring long-lasting benefits. Unfortunately,
much of the effort is, at present, directed at short-term objectives.
Mass chemotherapy as a control strategy has its own challenges,
among which are those of optimising community involvement and
participation. The recognition, acceptance, and commitment to
play the role that is expected of the communities are factors crucial
to achieving sustainable control programmes. Although global
funding for these programmes has increased markedly in recent
years, ‘‘donor fatigue’’ may set in as a major obstacle to sustained
funding if initial successes (which are invariably largest at the
beginning), are not maintained. The arsenal of available drugs for
MDA is limited, as most of them were developed originally for
parasites of veterinary importance in markets of middle- to high-
income economies,with very little or no development programmes
for new drugs specifically targeting human helminthiases. This
makes the existing control programmes highly vulnerable to the
possible development and spread of anthelmintic resistance. It is
also clear that the long-term control and eradication of these
helminth diseases will require improvements in sanitation and
hygiene, improved socioeconomic development, and environmen-
tal sustainability.
Increasing human population size, changes in demographic
patterns and activities, and changing agriculture and irrigation
practices are also altering the environment at an unprecedented
scale, further increasing the risk of STH and zoonotic helminthi-
ases [54,55]. How these activities will play out in the long term, as
well as what will be the effects of climate change on the
distribution and incidence of helminth infections, remains poorly
understood. Thus, whereas helminth diseases are often thought of
as chronic and ancient scourges of humanity, some may become
re-emerging diseases as new outbreaks are reported in response to
environmental and socio-political changes, migration, travel,
forced human displacement, and clean water shortages.
Control of S. japonicum and most cestode infections in humans is
also complicated by the fact that they constitute zoonotic
infections. For example, other animals, e.g., cattle, buffalo,
rodents, dogs, sheep, and pigs can act as reservoirs for human
transmission of S. japonicum. A more integrated strategy for control
of this species of schistosome is therefore required. A pilot study for
such an integrated control strategy for schistosomiasis has been
undertaken in China using a multi-pronged approach, including
health education, access to clean water and adequate sanitation,
mechanisation of agriculture, and fencing of water buffaloes, along
with chemotherapy [56–58]. In the case of cestode infections, and
despite the proven benefit of chemotherapy with praziquantel and
possibly albendazole for patients with parenchymal NCC [59,60],
there is a need for improved drugs and/or studies with drug
combination regimens and dosages to evaluate their efficacy [61].
Millions of doses of anthelmintics have been administered to
patently infected and exposed individuals in endemic areas, in
some cases for prolonged periods, and have undoubtedly yielded
health benefits for the treated populations. However, helminth
infections persist in their host populations, and are resilient to
control interventions (a consequence, in part, of their population
biology). Understanding the biological, environmental, and social
determinants of such persistence, as well as the driving forces of
new emerging and re-emerging public health challenges, is crucial
to steering research, harnessing the potential of new scientific
advancements, and engaging stakeholders to achieve the MDGs.
Reviews of the progress on the implementation of the MDGs
indicate that the attainment of the goals has been slow, in
particularly those related to health, namely, MDG4, reduce child
mortality; MDG5, improve maternal health; and MDG6, combat
HIV/AIDS, malaria and other diseases. This is particularly
worrying for many African countries. This slow progress is not
consistent with the actual increase in resources for health research
worldwide. However, it is important to pay attention to the fact
that only 5% of global research spending is estimated to actually
be applied to the needs of low- and middle-income countries, and
a miniscule fraction of this to the neglected helminth diseases. In
fact, though MDG6 specifically mentions HIV/AIDS and malaria
as critical targets for sustainable poverty reduction by the year
2015, it merely alludes to chronic parasitic worm infections as
‘‘other diseases’’ [2]. Because these diseases prevent the achieve-
ment of the first six MDGs, their control with cost-effective
interventions could be the basis for long-term economic growth
and development [2,4].
Althoughthe disabilityamongthe bottombillion thatresults from
NTDs, including the helminth diseases, is enormous, the NTDs
have not received nearly the same attention as three of the highest
mortality-causing infectious diseases, HIV/AIDS, malaria, and
tuberculosis [62]. This is likely because they are not perceived as
major causes of premature death. However, onchocerciasis can
cause visual impairment, blindness, and excess mortality both of the
blind and of heavily infected yet sighted individuals; LF can cause
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of people to work and look after themselves and others; STHs and
schistosomiasis can markedly reduce the growth and development
of children, including cognitive ability throughout life, as well as
increasing child mortality. Hookworm infection can cause anaemia
and impact on maternal health and neonatal mortality. In pregnant
women,the same infections may result inpremature birth, lowbirth
weight,and increased maternal morbidity and mortality. Liver fluke
infections can cause major liver pathology, including hepatic
cancer, while NCC is a major cause of seizure disorders and other
forms of neurological disease that can increase the level of poverty.
Box 2 summarises some of the driving forces that maintain
helminthiases as a challenge to the global public health community.
They are discussed more fully below.
Prof. David Molyneux, one of the leading advocates for NTDs
and helminthic control programmes, has said ‘‘My position has
always been that if you are going to do anything about the MDGs,
which have the overall objective of taking people out of poverty,
then you had better do something about the diseases which affect
the most people rather than those that affect the minority’’ [63].
However, to control the high-burden NTDs, including helminthi-
ases, in low- and middle-income countries and thus help achieve
the MDGs, a great deal of investment from both international and
national funding bodies will be required in order to develop the
facilities and the capabilities of scientists who can drive research
aimed at developing more effective tools and strategies to fight
infectious diseases of poverty [4]. Global financing mechanisms for
NTDs should take into consideration that disease control
programmes must be nationally owned, embedded into national
health plans, and backed by political commitment [4].
Another major issue that affects significantly the capacity of
several nations to reach the MDGs is the lack of trained human
resources, or the inability to retain those individuals who have
been trained, due to an inadequate environment for them to tackle
health problems within a research culture. Although some
countries are in the process of overcoming these difficulties, and
several high-level meetings on health research have called for
action on this respect (Mexico City, Abuja, Accra, Algiers, and
more recently Bamako), a clear commitment has not yet been
made by all participating nations. In Bamako, during the Call to
Action 2009 meeting, all stakeholders were urged to ‘‘promote and
share the discovery and development of, and access to, products
and technologies addressing neglected and emerging diseases
which disproportionately affect low- and middle-income coun-
tries’’. In countries where NTDs are endemic, different levels of
commitment toward their resolution, however, occur. A more
detailed discussion regarding these issues is presented in the review
entitled ‘‘A Research Agenda for Helminth Diseases of Humans:
Health Research and Capacity Building in Disease-Endemic
Countries for Helminthiases Control’’ [64].
Factors Driving the Persistence and Re-
Emergence of Helminth Infections of Humans
Parasite Population Biology and Human Host
Sociological Factors
Infection prevalence at any time-point may be high and this, in
addition to reflecting a high intensity of transmission, also results
from infections which are of long duration: parasites may have a
long life span, hosts do not recover and do not mount an effective
Box 2. Factors Driving the Persistence and Re-Emergence of Helminth Infections of Humans
N A disproportionate burden of helminthiases in human
populations occurs in marginalised, low-income, and
resource-constrained regions of the world that are
extremely poor and live with inadequate sanitation, which
contributes to a vicious circle of infection, poverty,
decreased productivity, and inadequate socioeconomic
development
N Polyparasitism; human helminthiases are characterised by
long-lasting infection with one or, more often, more than
one helminth and with other diseases
N Free-living stages of some STHs are very resistant to
environmental degradation and can persist in soil for years
N Parasite populations are strongly regulated within their
hosts (including definitive, intermediate, vector, and snail
hosts), which makes them highly stable and often resilient
to control interventions; therefore, premature cessation of
interventions may lead to re-emergence and eventually
restoration of the parasite population to baseline levels
N The control programmes rely heavily on anthelmintic
treatment and in many cases they depend on only one
drug. This makes the programmes vulnerable to the
possible development of anthelmintic resistance
N Optimum treatment coverage with MDA is required for the
success of control and elimination programmes for
helminthic infections. It also depends on community
involvement and participation, which needs to be opti-
mised and further encouraged
N Lack of highly effective tools, e.g., macrofilaricides or
vaccines, which can remove a high proportion of an
existing infection
N Increasing human population size and activities, and
changing agriculture and irrigation practices are also
altering the environment at an unprecedented scale,
further increasing the risk of zoonotic helminthiases
N Technical limitations of available diagnostic methods for
helminthiases impose significant constraints on current
initiatives to understand the epidemiology and control of
these infections
N A major obstacle to the implementation of cost-effective
control is the lack of accurate descriptions of the
geographical distribution of infection and co-infection
N Current diagnosis tools do not adequately identify true
infection status, parasite load, and do not account for
other confounding or interacting infections
N The distribution and burden of helminth infections are not
merely a reflection of geographical and ecological
circumstances, but also a reflection of the level of political
commitment and investment in human and financial
resources by national governments for the prevention
and control of helminthiases
N A multi-disease, inter-programmatic, and inter-sectorial
approach is not always taken wherever scientifically,
logistically, and economically possible in order to success-
fully control helminthiases
N Understandably, priority is given to ‘‘applied’’ or ‘‘opera-
tional’’ research at the expense of basic research; however,
a continuous effort to improve and update knowledge of
helminth fundamental biology is likely to yield improved
intervention and control tools
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repeated infection throughout their lives.
Further, aggregation of infection, whereby a minority of
individuals harbour very heavy infection but the majority of the
population harbour light or moderate infection, is a major factor
to consider in epidemiological studies and chemotherapy efficacy
trials, as well as in efforts to reduce prevalence, if, for example,
‘‘wormy’’ individuals are somehow missed in drug treatment
programmes.
Among the biological determinants of persisting infection is the
fact that parasite populations are strongly regulated within their
hosts, including definitive and intermediate hosts (arthropod
vectors, snail intermediate hosts, etc.), which makes them highly
stable and often resilient to control interventions. Therefore,
premature cessation of interventions may lead to re-emergence
and eventually restoration of the parasite population to baseline
levels. Among the sociological factors contributing to this stability
are those that link infection, and particularly heavy infection, with
chronic and long-lasting morbidity, disability, insidious and
irreversible effects on health, poor school performance, impaired
ability to work, low economic productivity, and premature death.
This perpetuates the vicious circle that links helminthiases to
poverty, lack of sanitation, poor hygiene, and marginalisation.
All of the above point towards the need to shift the intervention
paradigm from single to multi-disease, and to integrated
approaches to achieve sustained control of helminth infection.
There is also a need to develop indicators capable of capturing
meaningful impacts of multiple interventions such as reduced
anaemia, improved school attendance, and increased economic
productivity, as well as a need to evaluate the cost-effectiveness of
such interventions.
Chemotherapeutic Factors
The majority of the control programmes listed in Table 1 relies
heavilyon anthelmintictreatment. Overall they have achieved good
results with regards to effecting reductions on the prevalence and
intensity of infection and morbidity in some endemic areas [65–68],
and interruption of transmission for some infections, leading
towards local elimination, has been reported for some foci [69–
72] and even at the country level. Between 2000 and 2007, the
GPELF prevented LF disease in an estimated 6.6 million newborns
who would otherwise have acquired LF, thus averting in their
lifetimes nearly 1.4 million cases of hydrocoele, 800,000 cases of
lymphoedema, and 4.4 million cases of subclinical disease [11], and
achieving considerable economic benefits [73]. Examples of
elimination of transmission at a country level include the
achievements of the OCP in West Africa that, after 30 years of
concentrated efforts, prevented 600,000 new cases of onchocerciasis
and protected a total of 18 million villagers from the threat of
contracting river blindness [10]. Elimination of LF as a public
health problem has been successful in China and Korea [74–76],
proving that elimination of LF is possible given the necessary levels
of political support, adequate funding, public commitment, and
improvement of general socioeconomic conditions [76]. In
programmes where cohorts have been followed longitudinally from
the beginning of the interventions, reductions in the incidence of
infection and/or morbidity have been documented [77,78].
One reason for the heavy reliance on chemotherapy is because
for some programmes the drugs are donated by pharmaceutical
companies, or their cost has become affordable [2]. In this setting,
such interventions have been termed ‘‘a rapid-impact package’’
because the impact of anthelmintic treatment on parasite
populations is proportionally largest at the beginning of the
intervention. However, the long-term sustainability of the benefits
accrued depends critically on altering the environmental compo-
nents that facilitate transmission. Large-scale elimination of the
infection reservoir will depend on improving sanitation and
drainage, providing access to clean water, disposing adequately
of excreta and solid waste, promoting access to health services for
diagnosis and treatment, and facilitating adequate housing and
health education [79,80]. Anthelmintic treatment should therefore
be seen as a necessary, but not sufficient, condition towards
breaking the vicious circle between helminth infection, ill-health,
and chronic poverty.
Anthelmintic treatment can be distributed using a variety of
treatment strategies, depending on the level of infection endemic-
ity, the overall aim of the control programme (elimination of the
public health burden or of the infection reservoir), the population
groups that exhibit the highest infection levels, and the relationship
between infection and disease sequelae (for morbidity control).
Treatment can be aimed at particular occupational or age groups
(such as school-age children) most at risk of heavy infection and
severe morbidity. This is the basis for school-based health
programmes aimed at deworming children of STHs and
schistosomiasis. In this target population, treatment is adminis-
tered to all individuals regardless of their infection status. In areas
where community parasite burden is substantial, community
(mass) treatment is recommended. Other strategies include mass
screen and treat (MSAT) (targeting selective treatment to those
with patent and detectable infection), or treating individual cases
in clinical as opposed to community settings. The adoption of such
treatment modalities may also depend on the stage of the control
programme, with MDA implemented at its commencement, and
selective treatment in mopping-up phases. In programmes where
the aim is to eliminate the infection reservoir, the approach
adopted has generally been to treat the largest number of people at
the highest possible coverage for as long as autochthonous
transmission persists. However, this approach imposes strong
selection pressure upon parasite genomes, affecting genetic
diversity and favouring emergence of drug resistant strains. This
could lead to resurgence of infection in areas previously under
control.
Optimum treatment coverage with MDA is required for the
success of control and elimination programmes for helminthic
infections. Mathematical models predict, and experience confirms,
that population coverage is a key determinant of the success of
such programmes and that there remains a need to evaluate the
compliance of the population participating in such programmes
over the years. The use of the term ‘‘therapeutic coverage’’ implies
that the persons who receive the drugs are actually taking them
(i.e., they are compliant), but in several countries, most notably
India, a gap between coverage and compliance has been observed
in the case of LF [81,82]. The contribution of non-compliant
persons to transmission is unknown, but systematic non-compli-
ance may represent a potential threat for helminth control or
elimination. Furthermore, the sustainability of the required long-
term treatment programmes also raises issues of compliance
related to possible population fatigue, waning interest of
community drug distributors, and the necessary continuing
funding support from external donors, as the original funds which
initiated the treatment-based control programmes may be time-
limited.
Factors Associated with Current Ability to Diagnose
Helminth Infections in Individuals, Communities, and
Larger Spatial Scales
The technical limitations of available diagnostic methods for
helminthiases impose significant constraints on current initiatives
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are required for: disease mapping to guide initiation of
interventions; case-based diagnosis; and monitoring and evalua-
tion (M&E) of intervention programmes, particularly with the
possible threat of failure of the interventions due to technical
reasons and/or the development of drug resistance in the parasite
and insecticide resistance in vectors. An understanding of all these
factors will be important for determining the appropriate timing of
cessation of interventions in elimination settings, confirming
interruption of transmission, and learning what methods for
epidemiological surveillance in post-control areas are needed to
monitor resurgence or reinvasion of infections in areas where
elimination may have been certified.
For each of these activities, the technical requirements for
diagnostic tests are likely to be different, and may represent
different technical challenges. Furthermore, for each of the
helminth species considered here, the effect of the biology of the
parasite (life cycle, accessibility to parasitological diagnosis, body
fluid appropriate for sampling, role of and need to sample vector
or intermediate hosts), and the biology of the parasite–host system
(including age profiles of infection prevalence and intensity) on our
ability to diagnose infection status appropriately differs. In
addition, intensity of infection is a critical determinant of
morbidity and disease burden, and as described above, also
critical for the stability of the host–parasite relationship,
contribution to density-dependent, regulatory mechanisms of
parasite population abundance, and contribution to transmission.
Yet, with few exceptions, this critical parameter is difficult to
quantify accurately with present tools, or not at all quantified in
operational settings.
Not only is the diagnosis of individual infections important, but
also is the understanding of their spatial distribution within
countries, communities, and in individuals in which they may co-
occur. The effectiveness of large-scale integrated programmes for
the control of NTDs in general, and of helminth diseases in
particular, will depend on the geographical overlap between the
different NTDs. However, despite being co-endemic in particular
countries [83], different NTDs may, in certain settings, have
limited geographical overlap at sub-national scales, necessitating a
more geographically targeted approach for integrated NTD
control [79,84]. A major obstacle to the implementation of cost-
effective control is the lack of accurate descriptions of the
geographical distribution of infection. In recent years, considerable
progress has been made in the use of geographical information
systems (GIS) and remote sensing (RS) to better understand
helminth ecology and epidemiology, and to develop low-cost and
minimally invasive ways to identify target populations for
treatment such as the development of methods for rapid
epidemiological assessment (REA) of infection and morbidity
[85,86]. A significant constraint on such activities is the paucity of
accurate information on the distribution of infection prevalence
and intensity to build such maps. In China and Africa, predictive
maps have been prepared to identify risk areas and help
governments and health services to plan control strategies.
However, the potential of NTD mapping has been less exploited
in Latin America (but see [87] for REA methods and [88] for GIS
and onchocerciasis in the Amazonian focus [89]). Thus, research is
required to determine the optimal strategy for rapidly and
simultaneously assessing a number of NTDs so that more effective
implementation of integrated approaches for disease control can
take place. Reliable and updated maps of helminth infection
distributions are essential to design control strategies to target
those populations in greatest need; this current lack constitutes a
driving force of persisting control challenges. A principal
advantage of GIS platforms is that they facilitate the regular
updating of information, and provide a ready basis for analysis and
statistical modelling of spatial distributions [90].
Factors Associated with the Environmental and Social
Ecology of Human Helminthiases
The distribution and burden of helminth infections are not
merely a reflection of geographical and ecological circumstances,
but also a reflection of the level of political commitment and
investment in resources (human, financial) by national govern-
ments for the prevention and control of helminthiases in these
vulnerable populations and the environment they inhabit. Progress
has been slow in preventing, controlling, or eliminating these
diseases in some countries. Few health care systems can guarantee
full access to and delivery of the essential medicines for all patients
and populations at risk. Most countries have not yet fully taken
advantage of the new tools and protocols available for prevention,
control, and elimination. In order to develop an operative strategy
for the prevention and control of NTDs, there is a need to organise
public health resources.
For the infections that can be controlled by mass chemotherapy
(STHs, schistosomiasis), but not readily eliminated, early and
intensified case detection and management can be pursued.
However, although in some settings MSAT strategies have been
implemented (e.g., Brazil), more often than not, after some initial
assessment of prevalence and intensity, MDA is implemented; a
strategy that does not target infected individuals only. Normally,
clinical services are not required to implement such treatment as it
can be delivered by community distributors. The complex and
substantial epidemiological pattern of these infections in endemic
countries makes elimination challenging, particularly in areas of
high endemicity [91]. In specific circumstances, however, the
feasibility of achieving this goal is being considered (e.g.,
schistosomiasis in some Caribbean countries and low transmission
areas [92], and some isolated (island) foci in Africa such as on
Unguja, Zanzibar, http://score.uga.edu/Elimination.html).
Surveillance for NTDs should be the responsibility of national
and local health authorities, but there are challenges regarding the
availability of appropriate tools for this task (see review by
McCarthy et al. in this issue [93]). Moreover, given the reality that
most health care systems do not yet prioritise surveillance of
NTDs, outreach is needed to extend to and involve cooperating
health services, health professionals, environmental health officers,
and communities that can organise themselves for surveillance.
At a regional, supra-national level, a ranking order of the
relative importance of NTDs would be difficult to propose.
Rankings could be made based on criteria such as presence of
global or regional mandates for elimination, magnitude of
geographical extension, trends in distribution, and estimated
burden of disease. However, disease burden in particular is
challenging to establish due to lack of reliable data for many
NTDs, with factors such as incidence, prevalence, intensity,
association with morbidity and sequelae, distribution in afflicted
populations, and reliable demographic denominators of popula-
tions at risk are all of relevance. In any particular country or sub-
region, it will be necessary to prioritise which NTDs will be the
most important, based on updated knowledge on local prevalence,
disease burden, at-risk populations, geographical distribution, and
the commitment of governments to equity in health care (coverage
and health services goals). In the strategic lines of action to be
developed under this framework, a multi-disease, inter-program-
matic, and inter-sectorial approach should be taken wherever
scientifically, logistically, and economically possible. It should
actively seek community involvement, with the aim of increasing
www.plosntds.org 9 April 2012 | Volume 6 | Issue 4 | e1582local empowerment. In this way, the focus of implementation
should be through work in partnership with multiple sectors and
multiple health programmes. Failure to do so is also a driving force
of persisting, emerging, and re-emerging helminth infections and
the public health challenges they pose.
Factors Associated with Research Gaps and Overlooking
the Role of Basic Helminth Research
One of the main factors associated with the existence of research
gaps in basic helminth biology is the understandable priority given
to applied activities at the expense of basic research. ‘‘Under-
standable’’ because of the imperative to better control helminth
infections, or to at least relieve the morbidity associated with these
infections. The current efforts, based primarily on MDA, have
been effective in some cases (e.g., onchocerciasis, LF), but this
success has further eroded support for fundamental research.
However, MDA is potentially vulnerable to the development of
drug resistance in those cases where chemotherapy has had a
major impact on parasite prevalence and transmission (and hence
exerts a strong selective pressure), and has suffered from the lack of
suitable, safe, effective, and affordable drugs in other areas. For
example, although the macrocyclic lactone ivermectin has proven
effective in the interruption of onchocerciasis transmission in
specific epidemiologic settings, no safe and effective macrofilar-
icide (against adult worms or macrofilariae) exists. Likewise,
schistosome control depends critically on the sustained clinical
efficacy of praziquantel; the chemotherapy deployed to control
many helminth infections in a MDA setting is unsatisfactory, due
to the lack of safe and effective drugs amenable to single-dose
therapy. Furthermore, there is the hypothetical potential for
unintended consequences of MDA stemming from the poorly
understood dynamics of host–parasite interactions and interactions
between species parasitising the same hosts, and the changes that
altering parasite infection intensity and prevalence of some species
may have on those interactions.
What is needed is a balanced investment in basic research in
parallel to the operational activities that are being rolled out; the
dearth of funding available for basic research [94] undermines the
further improvement and future sustainability of the control efforts
already deployed and the consolidation of the gains that have been
achieved. What areas of basic research are likely to yield improved
control tools? Comparison of helminths with malaria may be
instructive in this context: genomics has transformed malaria
research over the past decade, reinvigorating drug and vaccine
development, and enabling the development of better parame-
terised mathematical models that may be used to inform control
and elimination efforts. A similar investment in helminth
genomics, most particularly in the development of functional tools
with which genome sequences can be probed and mined, could
catalyse a similar transformation of helminth research.
A major limitation on this front is the limited availability of
annotated genome sequences. With the advent of novel rapid and
inexpensive genome sequencing technologies, the entire genomes
of some selected helminths of medical importance have been
successfully sequenced. However, there is a lack of bioinformatic
tools, power, and reference genomes to accurately annotate them.
The genomes of B. malayi, S. mansoni, and S. japonicum have been
partially annotated, and a low-cost alternative for genome
sequencing, expressed sequence tag (EST), has been produced
for many helminths, which provide a glimpse of the transcriptome
of these species [95–100]. However, the complexity of helminth
life cycles, including the various developmental transitions they
undergo, makes it a daunting task to understand these transcrip-
tome profiles and, more importantly, the biological role of the
genes identified in these studies [101]. Functional genomic tools
such as RNA interference (RNAi) technology has proved to be
useful in deciphering the role of schistosome encoded proteins
[102–105]. In contrast, RNAi technology has been a largely
unsuccessful tool for functional analysis in parasitic nematodes
[106,107]. The exact reasons for this are still unclear, but is has
been suggested that some essential components of the RNAi
pathway are missing in some species of parasitic nematodes
[98,102].
Numerous studies have indicated that helminth-secreted
proteins, glycoproteins, and lipid-based molecules can interfere
with various host immune responses, ultimately leading to the
generation of an anti-inflammatory environment favourable for
the parasites’ survival [108–110]. Some of the processes affected
include the development of allergic responses [111,112] and
interference with host cytokine regulation and signal transduction
networks [113,114]. These findings highlight the complexity of the
biology of helminths with respect to the human/non-human
(definitive) hosts, and are further complicated by the effects of
Box 3. Gaps That Hinder Sustainability of
Control and Elimination Measures
Despite the many control initiatives that have been put in
place, helminthiases still persist as a public health problem.
To facilitate progress towards their control and elimina-
tion, it will be necessary to support research and
development of the following, which are required for
interventions to remain sustainable and thus bring long-
lasting benefits to the global public health community:
N Promote a better understanding and appreciation of the
importance of human helminthiases as causes of ill-
health and extreme poverty, so as to increase allocation
of resources for combating such infections, and, in
particular, to invest in a continuous effort to improve
and update knowledge of helminth fundamental biology
and to translate such knowledge into intervention tools
N Optimise existing intervention tools such as improved
formulation/combination of treatment regimens with
current/novel anthelmintics, control of vectors/interme-
diate hosts, as well as development of new pharmaceu-
ticals and vaccines
N Develop new diagnostic tools for determination and
quantification of: a) infection prevalence and intensity
that can aid more accurate mapping of helminth
infections; b) intervention impact in monitoring &
evaluation (M&E) protocols; c) possible anthelmintic
resistance; d) treatment end points
N Develop mathematical and statistical models for under-
standing parasite epidemiology; refining epidemiologi-
cal mapping; designing and implementing M&E and
surveillance of anthelmintic intervention; and determin-
ing criteria for safe cessation of MDA and post-control
surveillance
N Conduct research on the environmental and social
ecology of human helminthiases in order to improve
their control on a large scale and at sustainable levels
N Promote a better understanding of the role basic
research can play to facilitate knowledge and the
development of improved tools to further support
control and elimination measures, and thus bridge the
gap between basic research of helminth infections and
operational needs
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bacterial or viral infections. In addition, the importance of
Wolbachia, the bacterial endosymbiont of filarial nematodes, in B.
malayi, W. bancrofti, and O. volvulus has yet to be fully understood
with respect to the ultimate effects on host–parasite interactions
[115]. Wolbachia undoubtedly confer a survival advantage to B.
malayi and other filarial nematodes that enhances their parasitic
potential [116,117]. Further exploration of this interaction may
lead to development of novel methods of eliminating filarial
infections in host populations [118].
Despite the significant advances made in genomic, proteomic,
and transcriptomic profiles of helminths, these ‘‘omics’’ are still in
their early developmental stages. The influx of bioinformatic
knowledge needs to be reconciled with novel research methodol-
ogies for functional analysis of genes and the proteins they encode.
Since most countries afflicted by helminths are still classified as
developing, there is a divide between the available resources for
the application of basic research and what is available to scientists
in the endemic countries. Thus, the urgency required to explore
the incoming wealth of bioinformatic knowledge is skewed towards
the few research institutes in Western and developed countries that
have funding which normally has imposed priorities tailored
towards the funding agency’s interests and not necessarily the
actual needs of affected the population and countries [2].
Conclusion
The increasing acknowledgement of the burden imposed by
helminthiases, particularly since the last quarter of the 20th
century, has led to the implementation of large-scale control and
elimination programmes. Despite much advancement in control-
ling these diseases, obstacles remain that challenge the global
public health community. There is a clear need for an innovative
research framework that is thoroughly integrated with the
programmes, holistic in approach, collaborative and global in
perspective, and that assesses current understanding, identifies
gaps in knowledge, and seizes opportunities to address specific
needs and move the helminth control agenda forward. Although
millions of doses of anthelmintics have been administered to
patently infected and exposed individuals in endemic areas, in
some cases for prolonged periods, helminth infections still persist
in their host populations and they appear to be resilient to control
interventions (a consequence, in part, of their population biology).
Moreover, helminth diseases, which are often considered as
chronic and ancient scourges of humanity, may become re-
emerging diseases as new outbreaks are reported in response to
environmental, demographic, and socio-political changes, migra-
tion, travel, forced human displacement, and shortages of clean
water. Understanding the biological, environmental, and social
determinants of such persistence, as well as the driving forces of
these emerging and re-emerging public health challenges, is
crucial to steering the needed research and to harness the potential
of new scientific advancements that can be translated into
improved or novel intervention tools. It is important to remember
that a large-scale elimination of the infection reservoir will also
depend on improving sanitation, providing access to clean water,
disposing adequately of excreta and solid waste, promoting access
to health services for diagnosis and treatment, and facilitating
adequate housing and health education. Box 3 lists some of the
research gaps identified in five major research themes, including
interventions, diagnostics, basic biology, mathematical modelling,
social and environmental determinants, and capacity building, and
that hinder sustainability of control and elimination measures, and
which will be more extensively described in the following reviews.
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